bims-raghud Biomed News
on RagGTPases in human diseases
Issue of 2026–11–22
eleven papers selected by
Irene Sambri, TIGEM



  1. J Cell Biol. 2026 Dec 07. pii: e202411213. [Epub ahead of print]225(12):
      Peroxisomes are dynamic metabolic organelles whose dysfunction results in severe diseases. The homeostasis of peroxisomes is also ensured through pexophagy, a type of selective autophagy targeting these organelles. Pexophagy can be activated by several stressors, such as starvation, mTOR inhibition, and iron deficiency. However, the regulatory mechanisms underlying pexophagy are poorly characterized. Here, we identify a novel regulatory axis of iron deficiency-induced pexophagy, which preferentially engages GABARAP among the mATG8 family members. Comparative analysis of the mATG8 interactomes reveals that upon iron depletion, GABARAP selectively interacts with the tumor suppressor complex FLCN/FNIP1 triggering the activation of the autophagy and lysosome transcription factors TFEB and TFE3, thus promoting efficient cargo degradation. Our findings thus identify the GABARAP-FLCN/FNIP1 axis as a molecular sensor that bridges iron deficiency and TFEB/TFE3 activation to prime pexophagy execution.
    DOI:  https://doi.org/10.1083/jcb.202411213
  2. Int J Biol Macromol. 2026 Nov 16. pii: S0141-8130(26)05274-8. [Epub ahead of print] 155320
      Beyond their roles as substrates for protein synthesis, amino acids serve as potent signaling molecules that convey nutrient availability to the mechanistic target of rapamycin complex 1 (mTORC1), a central regulator of cellular growth, metabolism, and autophagy. This nutrient-dependent regulation relies on a diverse network of sensors distributed across extracellular, cytosolic, and lysosomal compartments. Despite their mechanistic diversity, these pathways converge on the GATOR-Rag GTPase axis to dictate the lysosomal recruitment and activation of mTORC1. Here, we propose a conceptual framework that organizes amino acid sensors according to their subcellular localization, modes of nutrient recognition, and signaling outputs, categorizing them into direct metabolite-binding sensors, stress-responsive sensors, and enzymatic sensors. Drawing on recent structural, biochemical, and physiological insights, this review contrasts how these disparate sensors modulate mTORC1 activity and examines the principles governing multi-nutrient integration. Furthermore, we evaluate the pathological implications of dysregulated amino acid sensing in cancer, metabolic diseases, and neurological and neuropsychiatric disorders. Finally, we highlight recent advances in pharmacologically targeting amino acid-sensing pathways, particularly the modulation of Sestrin-dependent leucine sensing as an emerging strategy for depression.
    Keywords:  Amino acid sensing; CASTOR; Rag GTPase; SAMTOR; Sestrin; mTORC1
    DOI:  https://doi.org/10.1016/j.ijbiomac.2026.155320
  3. Am J Nephrol. 2026 Oct 23. pii: ablag030. [Epub ahead of print]
       BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney disorders characterized by the progressive formation of renal cysts. It is a systemic disease with significant extrarenal manifestations. Among these, cardiac electrical abnormalities are increasingly recognized as clinically important yet underappreciated contributors to cardiovascular morbidity and mortality.
    SUMMARY: Beyond cyst formation, pathogenic variants in PKD1 or PKD2, which encode polycystin-1 and polycystin-2, respectively, interfere with calcium homeostasis, mechanotransduction, and mitochondrial function in both kidney and heart tissues. These molecular changes trigger a cascade of pathological events, including renin-angiotensin-aldosterone system activation, transforming growth factor-driven fibrosis, and oxidative stress, leading to structural and electrical remodeling of the heart. These alterations contribute to cardiac electrical remodeling, manifesting clinically as QT interval and corrected QT (QT/QTc) prolongation, left ventricular hypertrophy, atrial fibrillation, ventricular arrhythmias, and other electrocardiographic abnormalities. Despite growing evidence, cardiac electrical abnormalities in ADPKD remain understudied in clinical practice. Early detection of subclinical cardiovascular abnormalities may be facilitated by electrocardiographic monitoring, cardiac imaging, and complementary biomarker assessment. Additionally, findings from iPSC-derived cardiomyocyte models support the translational potential of personalized drug-screening platforms.
    KEY MESSAGES: This review summarizes current evidence linking polycystin dysfunction to cardiac electrical abnormalities in ADPKD by integrating molecular mechanisms with experimental and clinical findings. It also highlights the need for integrated cardio-renal approaches to improve cardiovascular surveillance, risk stratification, and future therapeutic development in ADPKD.
    Keywords:  ADPKD; Calcium signaling; Cardiac electrical abnormalities; Cardiac electrophysiology; Cardiorenal axis; Polycystins
    DOI:  https://doi.org/10.1159/ajn/ablag030
  4. Nat Commun. 2026 Oct 21. pii: 11829. [Epub ahead of print]17(1):
      The transcription factor TFE3 coordinates cellular adaptation to stress. While its acute activation is cytoprotective, chronic TFE3 dysregulation is linked to diverse pathologies. Here, we characterize the cellular landscape of TFE3-NDD, a recently described neurodevelopmental disorder caused by mutations that disrupt the TFE3-Rag GTPase interface, leading to constitutive TFE3 nuclear localization. Using patient-derived fibroblasts, we show that TFE3-NDD is primarily a metabolic and homeostatic disorder. Mutant cells undergo a profound rewiring toward oxidative phosphorylation (OXPHOS), resulting in metabolic rigidity and a vulnerability to energy failure. Despite a massive expansion of the lysosomal compartment, we observe a paradoxical qualitative failure characterized by impaired acidification, defective protease maturation, increased lysosomal exocytosis, and aberrant cathepsin K secretion. This secretory phenotype is coupled with a destabilized cell-extracellular matrix interface, marked by impaired migration, defective coordination between actomyosin tension and focal adhesion maturation, and a loss of synaptic stabilizers. Notably, TFE3-NDD shares a signature of high OXPHOS and ferroptosis resistance with TFE3-dependent cancers, such as translocation renal cell carcinoma. Our findings reveal how the chronic hyperactivation of a protective stress-response factor collapses cellular homeostasis, providing a mechanistic framework for the tissue malformations and neurodevelopmental deficits that define TFE3-NDD.
    DOI:  https://doi.org/10.1038/s41467-026-78845-7
  5. Kidney Int. 2026 Dec;pii: S0085-2538(26)00829-X. [Epub ahead of print]110(6): 1348-1350
      Human kidney organoids provide genetically tractable models of polycystic kidney disease, but variable cyst formation and limited scalability have constrained their use in drug discovery. Vanichapol et al. describe a scalable suspension culture of ureteric epithelium-like organoids in which PKD2 loss drives rapid, spontaneous, and highly penetrant cystogenesis. The study advances organoid-based drug screening for polycystic kidney disease, identifies Toll-like receptor 4 signaling as a candidate regulator of cyst growth, and highlights how epithelial identity and maturation state shape drug responses.
    DOI:  https://doi.org/10.1016/j.kint.2026.09.020
  6. Life Sci. 2026 Nov 20. pii: S0024-3205(26)00593-X. [Epub ahead of print] 124784
       AIMS: Elevated plasma S-adenosylhomocysteine (SAH) levels increase the risk of atherosclerotic cardiovascular disease. Since lipophagy maintains cholesterol homeostasis through hydrolysis of cholesterol esters to support efflux, its impairment reduces cholesterol efflux. We aimed to explore the association of elevated SAH with macrophage foam-cell cholesterol handling and the potential mechanisms involving autophagy-related lipid processing and cholesterol efflux.
    MATERIALS AND METHODS: We explored the associations between plasma SAH levels and cholesterol efflux capacity (CEC) in the Guangdong Coronary Artery Disease (CAD) Cohort. Adenosine dialdehyde (AdOx) was used to increase intracellular SAH levels in THP-1 macrophage foam cells, followed by evaluation of cholesterol efflux and autophagy-related lipid handling. We investigated the molecular mechanisms by examining regulators, including ABCA1, vacuolar-type H+-ATPase (V-ATPase) subunits, and transcription factor EB (TFEB). Torin 1 was used to assess changes in TFEB-related signaling and cholesterol efflux.
    KEY FINDINGS: We found that plasma SAH levels were inversely associated with CEC in CAD patients. In vitro, AdOx treatment increased intracellular SAH and reduced ABCA1 expression and ApoA-I-dependent cholesterol efflux. AdOx treatment was accompanied by reduced TFEB nuclear translocation, lower ATP6V1H and lysosomal acid lipase (LAL) expression, altered LC3/p62 levels, and increased lysosomal cholesterol. Torin 1 partially restored TFEB-related gene expression and ApoA-I-dependent cholesterol efflux. These findings support the involvement of TFEB-V-ATPase-related lysosomal signaling in AdOx-associated changes in macrophage cholesterol handling.
    SIGNIFICANCE: Elevated S-adenosylhomocysteine is associated with impaired macrophage cholesterol efflux involving alterations in TFEB-V-ATPase lysosomal signaling, identifying SAH metabolism and TFEB-V-ATPase signaling as potential targets for further investigation.
    Keywords:  Cholesterol efflux; Lipophagy; S-Adenosylhomocysteine; Transcription factor EB; Vacuolar-type H(+)-ATPase
    DOI:  https://doi.org/10.1016/j.lfs.2026.124784
  7. J Pathol. 2026 Nov 17.
      The intraneuronal accumulation of amyloid-β (Aβ) is an early pathogenic event in Alzheimer's disease (AD), initiating a pathological cascade that includes synaptic dysfunction, metabolic deficits, and eventual neuronal loss. Transcription factor EB (TFEB), a master regulator of the autophagy-lysosomal pathway (ALP) and mitochondrial homeostasis, represents a promising therapeutic target. However, its efficacy and mechanisms when specifically activated in neurons during the prodromal stage remain unclear. Here, we used an adeno-associated virus (AAV) under the control of the CaMKIIα promoter to achieve excitatory neuron-specific TFEB overexpression in the hippocampal CA1 region of 2 months-old 5×FAD mice. This intervention significantly reduced soluble Aβ levels at 3 months and attenuated amyloid plaque burden, dystrophic neurite formation, and glial activation at 6 months, accompanied by substantial improvements in spatial learning and memory. Mechanistically, transcriptomic and functional analyses revealed that TFEB not only enhanced autophagic flux and lysosomal biogenesis but also promoted the expression of key mitochondrial genes and improved mitochondrial function. In APP695swe-N2a cells, TFEB overexpression increased levels of LC3B-II and LAMP1, enhanced mitochondrial activity and biogenesis (via PGC-1α upregulation), and effectively reduced intracellular Aβ accumulation. Our findings demonstrate that targeted TFEB overexpression in excitatory neurons during early AD pathogenesis initiates a protective cascade by co-activating autophagy-lysosomal clearance and mitochondrial pathways, thereby reducing Aβ accumulation and mitigating downstream pathology. This study highlights the potential of neuron-specific TFEB activation as a cell-type-specific therapeutic approach for early AD intervention. © 2026 The Pathological Society of Great Britain and Ireland.
    Keywords:  5×FAD; Alzheimer's disease; TFEB; amyloid‐β; autophagy; excitatory neuron; lysosome; mitochondria
    DOI:  https://doi.org/10.1002/path.70153
  8. Front Pharmacol. 2026 ;17 1972918
      Tuberous sclerosis complex (TSC), caused by pathogenic variants in TSC1 or TSC2, is frequently associated with early-onset and drug-resistant epilepsy. Loss of hamartin-tuberin activity causes Rheb-dependent mTORC1 hyperactivation and provides the mechanistic basis for mTOR-directed treatment with everolimus, but mTORC1 activation alone does not fully account for variation in seizure burden or treatment response. Evidence from biochemical and disease-model studies indicates that TSC1/TSC2 also interacts with canonical Wnt/β-catenin signaling through GSK3β and Axin, while cellular metabolism may provide an additional point of convergence through AMPK-dependent regulation of TSC2. This narrative review examines the biochemical, neuronal, human-tissue, pharmacological, and clinical evidence for this Wnt-GSK3β-TSC2-mTOR framework and distinguishes established findings from context-limited, emerging, and hypothetical relationships. Everolimus remains the established mechanism-based therapy for TSC-associated refractory seizures, whereas metformin has the strongest TSC-specific clinical signal among the investigational metabolic approaches discussed. GLP-1 receptor agonists and direct GSK3β modulation remain preclinical or mechanistically speculative in this setting. Gene- and RNA-based approaches provide emerging precedents for pathway-selective intervention, but none has directly targeted the Wnt-GSK3β-TSC2 interface. The principal unresolved question is whether this signaling relationship operates in human TSC epileptogenic tissue. Direct tissue-level validation, followed by selective pathway interrogation and adequately powered therapeutic studies, is needed before Wnt-directed strategies can be considered clinically relevant in TSC-associated epilepsy.
    Keywords:  GSK3β; Wnt/β-catenin signaling; epilepsy; epileptogenesis; everolimus; mTOR; metformin; tuberous sclerosis complex
    DOI:  https://doi.org/10.3389/fphar.2026.1972918
  9. EMBO Mol Med. 2026 Nov 17.
      Mitochondria and lysosomes are central regulators of cellular metabolism, nutrient sensing, cellular quality control, and stress adaptation. Although traditionally studied as independent organelles, it is now evident that they operate as an integrated functional network through multiple modes of communication, including membrane contact sites, signaling pathways, and selective vesicular trafficking. Disruption of this crosstalk is increasingly recognized as a common feature of mitochondrial disorders, lysosomal storage diseases, neurodegeneration, cardiovascular disease, and aging, highlighting its importance for cellular and tissue homeostasis. While mitophagy has long been considered the principal interface between mitochondria and lysosomes, recent discoveries have revealed a much broader communication landscape in which bidirectional signaling, ion exchange, lipid transfer, and mitochondria-derived vesicles coordinate organelle function independently of bulk degradation. In this Review, we discuss the molecular mechanisms that mediate mitochondria-lysosome communication, emphasizing emerging concepts in inter-organelle signaling and membrane contact biology. We further examine how disruption of these pathways contributes to human disease and consider the growing evidence that restoring mitochondria-lysosome communication, rather than targeting either organelle in isolation, represents a promising therapeutic strategy.
    DOI:  https://doi.org/10.1038/s44321-026-00556-9
  10. Adv Sci (Weinh). 2026 Nov 19. pii: e78240. [Epub ahead of print]
      Although the Hippo pathway is a well-established negative regulator of the YAP/TAZ-TEAD1-4 transcriptional complex, the molecular mechanisms that actively sustain YAP/TAZ-TEAD activation remain poorly defined. Integrating recent literature with systematic Cancer Dependency Map (DepMap) codependency analysis, we propose a working model wherein the TAZ/YAP-TEAD complex functions as a nuclear executor of the focal adhesion mechanotransduction cascade. This mechanotransduction arm is predicted to initiate at the plasma membrane by integrins αvβ5 (ITGAV/ITGB5), N-cadherin (CDH2), and lysophosphatidic acid receptor 1 (LPAR1), which likely engage PKN2 and MARK2/3 signaling kinases downstream of the focal adhesion complex. Conversely, a cell-surface triad comprising NRP1, PLXNA1, and KIRREL1 and EPHA2 may act as an upstream activator of the inhibitory Hippo pathway. Collectively, we propose that TAZ/YAP-TEAD activity is governed by a dynamic, reciprocal antagonism between the Hippo pathway and focal adhesion-mediated mechanotransduction, with the latter serving as a positive driver sustaining YAP/TAZ functional activity.
    Keywords:  Hippo pathway; TAZ; TEAD; YAP; focal adhesion complex; mechanotransduction; signal transduction
    DOI:  https://doi.org/10.1002/advs.78240
  11. Pharmacol Ther. 2026 Nov 15. pii: S0163-7258(26)00173-7. [Epub ahead of print]289 109146
      The Hippo-YAP/TEAD signaling axis regulates tissue growth, cellular identity, and organ homeostasis. Dysregulation of this pathway, through NF2 loss, LATS1 or LATS2 inactivation, or YAP1- or WWTR1-derived gene fusions, results in persistent nuclear localization of YAP/TAZ, driving TEAD-dependent transcriptional programs. NF2-deficient and YAP1/TAZ-driven tumors, such as mesothelioma, schwannoma, meningioma, and epithelioid hemangioendothelioma, exemplify Hippo-pathway dependency and are potential therapeutic targets. Targeting TEAD disrupts transcriptional circuits sustaining tumor growth, plasticity, and immune suppression while modulating metabolic and stromal dependencies. Pharmacologic interventions targeting YAP/TEAD include TEAD palmitate-binding pocket inhibitors, direct YAP/TEAD protein-protein interaction disruptors, PROTAC-mediated TEAD degraders, and YAP-directed antisense oligonucleotide strategies. Early-phase trials have demonstrated preliminary clinical activity, particularly with TEAD palmitate-binding pocket inhibitors in mesothelioma and have been associated with mild drug-related toxicities, such as proteinuria. YAP/TEAD inhibition may also be a rational combinatorial approach given the emergence of adaptive resistance mechanisms to EGFR/KRAS inhibitors and immunotherapies. Collectively, these findings provide rationale and early proof-of-concept for the pharmacologic targeting of the YAP/TEAD pathway. In this review, we describe the biological underpinnings of the YAP/TEAD pathway in cancer medicine, the anti-cancer strategies targeting this pathway, and discuss future directions in the field.
    Keywords:  Drug resistance; Hippo signaling pathway; Mesothelioma; Molecularly targeted therapy; Transcription factors; Transcriptional coactivators; YAP-signaling proteins
    DOI:  https://doi.org/10.1016/j.pharmthera.2026.109146